Short answer
Tectonic Therapeutic, Inc. (TECX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$21M
- −12.1% YoY · +4.2% QoQ
- EPS (diluted)
- −$1.08
- −5.9% YoY · +8.5% QoQ
Source: XBRL data from the Tectonic Therapeutic, Inc. (TECX) Q3 2026 10-Q on SEC EDGAR. USD.
Tectonic Therapeutic, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales
- Operating expenses $23.5M vs $21.9M YoY, operating loss $23.5M vs $21.9M
- Best program: TX45 R&D $5.7M vs $6.0M, down $0.4M; highest spend: platform $8.4M vs $7.0M
- Cash $234.7M at September 30; nine-month operating cash use $54.8M vs $45.6M
- APEX topline results expected by January 2027; TERRA planned by year-end 2026 amid additional funding needs
Risk Factors
- Newly added regulatory risk: September 2026 FDA Fast Track designation for TX2100 does not assure accelerated review or marketing approval
- Most materially updated market risk: AstraZeneca discontinued AZD3427 in February 2026, while AZD5462 showed Phase 2 efficacy, heightening relaxin-pathway competition
- Compliance risk: December 2025 BIOSECURE Act could restrict work with designated Chinese biotechnology companies, threatening TX45 supply
- Operational risk: WuXi Biologics remains the sole TX45 supplier, exposing clinical timelines to manufacturing disruption
- Financial risk: $234.7 million cash and cash equivalents as of September 30, 2026, expected to fund operations for at least 12 months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tectonic Therapeutic, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.